Rational Design of Inhibitors of Yersinia pestis EF-Tu

鼠疫耶尔森氏菌EF-Tu抑制剂的合理设计

• 批准号: 6692015
• 负责人: Maxim Totrov
• 金额: $ 49.94万
• 依托单位: MOLSOFT, LLC
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6692015
• 关键词: Escherichia coli; Salmonella typhimurium; Yersinia pestis; antibacterial agents; binding sites; drug design /synthesis /production; drug discovery /isolation; ligands; protein structure; three dimensional imaging /topography; transcription factor

DESCRIPTION (provided by investigator): The lack of reliable wide-spectrum antibiotics and rapid emergence of antibiotic resistance in dangerous pathogens poses immediate threats for human health generally and major biodefense concerns. Novel classes of antimicrobial compounds uncompromised by resistance and targeting highly conserved, functionally critical molecular sites in bacteria are urgently needed. Elongation Factor Tu (EF-Tu) is an optimal target for broadly reactive antimicrobials: EF-Tu has at least three functionally relevant binding pockets essentially identical among many bacterial species, including E. coli, S. typhimurium and S. flexneri, V. cholerae, and plague agent Yersinia Pestis. Recently solved by Dr. Frances Jurnak, UC-Irvine, the 3D structures of EF-Tu protein co-crystallized with natural antibiotics explain the atomic details of inhibitor activity of these molecules and provide a solid basis for rational design of new, safe and effective antimicrobials. Our application combines Dr. Jurnak's structural studies with Molsoft's state of the art flexible docking and virtual ligand screening capabilities, and Chemical Diversity Laboratories' expertise in parallel synthesis, biochemical and biological assays to discover new antibiotics in a rapid, structure-focused manner.

描述(由研究人员提供)：缺乏可靠的广谱抗生素，在危险病原体中迅速出现抗生素耐药性，对人类健康构成直接威胁，也是主要的生物防御问题。迫切需要不受耐药性影响的新型抗菌化合物，并以细菌中高度保守的、功能关键的分子位点为靶点。延伸因子Tu(EF-Tu)是广谱抗菌剂的最佳靶标：EF-Tu至少有三个功能相关的结合口袋，在许多细菌物种中基本相同，包括大肠杆菌、鼠伤寒沙门氏菌和福氏沙门氏菌、霍乱弧菌和鼠疫耶尔森氏菌。加州大学欧文分校France Jurnak博士最近解决了EF-Tu蛋白与天然抗生素共结晶的3D结构，解释了这些分子抑制活性的原子细节，为合理设计新的、安全有效的抗菌剂提供了坚实的基础。我们的应用将Jurnak博士的结构研究与Molsoft最先进的灵活对接和虚拟配体筛选能力以及化学多样性实验室在平行合成、生化和生物检测方面的专业知识相结合，以快速、专注于结构的方式发现新的抗生素。